Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06197126

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female MRI Neoplasms Neoplasms by Site Prognostic Model Radiotherapy Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

20 year–85 year

Sex eligibility

Female

Study type

Observational

Primary location

Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China

About this study

Even with the development of advanced technology, the prognosis for CC patients who received radiotherapy is still an intractable problem. Almost 40% suffered disease recurrence among locally advanced patients after radiotherapy and the reported 5-year overall survival is 50-70%. The present FIGO staging is controversial in pre-treatment assessment, which is mainly based on physical examination. An ambiguous diagnosis leads to different treatment strategies and follow-up plans, which is associated with prognosis non-improvement. Incorporation of the tumor involvement features based on the MRI into pre-treatment assessment could standardize and improve the consistency and repeatability of diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) pathologically confirmed CC, (2) initially treated in our center

Exclusion criteria

  • (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up

Treatment and study plan

Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .

Radiation

The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.

Other names: concurrent chemothearpy

Primary outcomes

  1. overall survival

    Time frame: 1-36 months

    the interval from diagnostic day to death or the last follow-up

Secondary outcomes

  1. progression-free survival

    Time frame: 1-36 months

    the interval from diagnostic day to death, the last follow-up, or the onset of regional recurrence or distant metastasis

Study contacts

Contact information is provided by the study sponsor or research team.

Yang Sun

CONTACT

[email protected]

+8615959028989

Sponsors and collaborators

Lead sponsor

Fujian Cancer Hospital

Other Gov

Registry information

Official study title

A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Jan 9, 2024
Registry last updated
Jan 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.